However, more than a decade later, studies contradicted these findings by demonstrating that MCAM expression enhances motility in breast cancer cell lines and characterized it as a “prometastatic factor associated with poor prognosis histoclinical features” as described above [129]. This evidence concerns the gene MCAM and breast carcinoma.